Artificial intelligence is an invention that is definitely changing the world. One of the most interesting areas of its use is the medical industry. Soon, all pharmaceuticals discovered and produced using AI will be available in pharmacies. This industry is also associated with the use of artificial intelligence for medical products. On the one hand, it is about using it for clinical trials on a specific product, i.e. taking advantage of the AI program to introduce this product to the market faster. On the other hand, it is about authorizing a specific medical product whose operation will be based on the use of AI.
The Human Cell Atlas (HCA) is a groundbreaking global initiative aimed at mapping all human cell types to transform our understanding of health and disease. By creating a detailed reference map of human cells, the HCA is poised to advance medical research, enabling better disease diagnosis, treatment, and prevention. Using cutting-edge technologies like single-cell genomics and spatial analysis, the project is generating vast amounts of data, with global participation from over 3,200 scientists across 99 countries. The HCA’s findings have significant medical implications, including insights into disease mechanisms, personalized therapies, and rapid responses to health crises like the COVID-19 pandemic. Despite its vast potential, the HCA faces challenges, particularly in ensuring global equity and navigating complex ethical and legal issues like data protection and intellectual property. Efforts to create an inclusive, diverse, and open data-sharing platform are crucial, but disparities in infrastructure and knowledge between high-income and low- to middle-income countries remain barriers. Addressing these challenges with robust ethical frameworks, data protection measures, and clear intellectual property guidelines is essential to the HCA’s success. Ultimately, the HCA aims to provide a transformative resource that enhances human health while fostering global collaboration and inclusivity.
The Ministry of Health in Poland has proposed a number of draft laws aimed at combating the sale of electronic cigarettes and heated tobacco products. The new regulations will concern the amendment of the Act of 9 November 1995 on the protection of health against the effects of using tobacco and tobacco products (consolidated text: Journal of Laws of 2024, item 1162), hereinafter referred to as the “Tobacco Act”. The Government Legislation Centre website currently presents draft laws prohibiting the sale of nicotine-free electronic cigarettes to persons under 18 years of age and introducing the definition of a heated tobacco product into the Tobacco Act. The Ministry of Health has also announced a draft law on a complete ban on the sale of disposable cigarettes.
Ban on the sale of electronic cigarettes to persons under 18 years of age and other restrictions
According to Food and Drug Administration (FDA), a ‘generic drug’ is the same as a brand name drug in many aspects such as dosage, safety, strength, how it is taken, quality, performance, and intended use. On the other hand, the term supergeneric is applied to the development process for small molecule drugs which represent new therapeutic entities which demonstrate an improvement in either product delivery, design or through the application of a more efficient manufacturing process.
The risk analysis should take into account real threats to data processing and properly estimate their level. Risk analysis cannot be a superficial activity performed solely to meet the formal requirements of the personal data protection regulations, because then it does not function as an effective way to minimize threats – learnings from the most current decision of the Polish Office for Personal Data Protection imposing a fine on a medical company undergoing ransomware attack.
